Kimberly-Clark Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KMB research report →
Range $105 – $120
Price Chart
About the company
Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care products in the United States. It operates in two segments, North America and International Personal Care. The North America segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers, and other related products under the Huggies, Pull-Ups, Goodnites, Kotex, Poise, Depend, Kleenex, Scott, Cottonelle, Viva, Wypall , and other brand names.
- CEO
- Michael D. Hsu
- IPO
- 1980
- Employees
- 36,000
- HQ
- Dallas, TX, US
Get TickerSpark's AI analysis on KMB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $35.97B
- P/E
- 10.89
- Fwd P/E
- 14.80
- PEG
- 0.16
- P/S
- 2.17
- P/B
- 11.70
- EV/EBITDA
- 12.87
- Div Yield
- 4.72%
- Gross Margin
- 36.48%
- Op Margin
- 14.54%
- Net Margin
- 19.93%
- ROE
- 162.62%
- ROIC
- 16.53%
Latest fiscal year · YoY change
- Revenue
- $16.45B-18.0%
- Gross Profit
- $5.92B-17.5%
- Op Income
- $2.35B
- Net Income
- $2.02B-20.6%
- EPS
- $6.09-19.7%
- OCF Growth
- -14.1%
- FCF Growth
- -34.8%
- Beta
- 0.28
- RSI (14)
- 46
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kimberly-Clark said third-quarter results were solid despite one-off headwinds, while the newly closed Kenvue deal shifts the story toward integration, synergies, and a multi-year growth reset.· November 5, 2026
- Kenvue acquisition closed this week; management framed it as a "defining moment" and said the new company is focused on a three-phase plan: ready, set, and grow.
- Management said Q3 was solid overall, but North America was hurt by retailer inventory changes, a delayed product launch, and club distribution shifts in baby care.
- The team kept fiscal 2026 guidance intact, citing stronger underlying momentum, easier Q4 comps, and cost-mitigation actions already taken.
- 2027 will be a transition year with mid-single-digit EPS dilution versus standalone Kimberly-Clark, then a snapback in 2028 on a compounded basis.
- Synergy plans remain on track, with $1.9 billion of cost synergies and management saying some transformation opportunity is not included in that number.
Management did not provide a full Q3 income statement in the prepared remarks, but it said Kenvue’s Q3 organic growth was about 3%, North America tissue gained 20 basis points of share on a weighted basis, and Kenvue self-care and essential care were also up 3% organically. On costs, the company now expects full-year gross inflationary impacts of around $250 million, with about $50 million in Q2 and roughly $200 million in the second half; gross productivity was 6.1% year to date and 5.8% in Q3. For pricing, management said year-to-date total company pricing is down about 70 basis points and North America pricing is down about 80 basis points, but pricing for the full year is expected to land relatively flat. Forward-looking, management said it remains on track to about a two times leverage level by the end of the second year of the transaction; 2027 EPS should be mid-single-digit dilutive versus standalone KC, and 2028 should return to mid- to high-single-digit EPS growth on a two-year compounded basis versus 2026 standalone KC.
Mike Hsu emphasized that the acquisition creates a new health and wellness company with broader reach in everyday health, and he framed the strategy as "better care in more hands to enable smarter health." His tone was upbeat and confident, but also very execution-focused: he repeatedly stressed a boring, seamless integration, disciplined operating model, and reinvestment in brands rather than short-term financial optics. He said the base business remains strong, Kenvue’s momentum is improving, and the combined company has a long runway for growth if it executes on fundamentals.
Nelson Urdaneta focused on financial discipline, saying the company is on track or ahead on the deal metrics laid out a year ago, including synergy pacing, cost of capital, and operating momentum. He quantified the synergy target at $1.9 billion of cost synergies, with roughly a third from G&A, about 30%-40% from COGS, and the rest from sales and marketing/trade optimization. He also said the company expects about $250 million of full-year inflation, with incremental mitigation from revenue growth management and productivity, and he reiterated the leverage target of about 2x by the end of year two. On 2027 modeling, he confirmed mid-single-digit EPS dilution versus standalone KC, with amortization kept in non-GAAP metrics, and said 2028 should deliver mid- to high-single-digit EPS growth on a compounded basis.
Analysts focused on 2026 guidance confidence, 2027 dilution, North America softness, Kenvue brand momentum, diapers, China recovery, and the size/quality of revenue synergies. Management said 2026 guidance is supported by stronger underlying momentum, easier Q4 comps, and cost actions already taken, while 2027 is expected to be a reset year with mid-single-digit EPS dilution versus standalone KC before growth re-accelerates in 2028. On brand health, Hsu said Kenvue’s issues were mostly executional rather than structural, cited improving organic growth and stronger performance in OTC and hair, and said some categories like skincare and oral care still need assortment, creative, and execution work. On China diapers, he said demand has stabilized and improved slightly after false allegations were refuted, but recovery will take time, while on synergies the company clarified that the $1.9 billion target refers to cost synergies only, not revenue synergies.
The call presented a credible path to a larger, more diversified consumer-health platform, with management saying Kenvue’s brands are already showing improving momentum and the combined company is on track with deal milestones. Bullish investors could point to the $1.9 billion cost synergy target, easier comps, productivity gains, and management’s confidence that the integration will create room to reinvest and accelerate growth over time.
The main risks are execution and timing: North America has been soft, China diaper demand is still subdued, and management admitted some brands need resets in assortment, creative, and execution. The company also flagged 2027 as a dilution year versus standalone KC, and it said some share losses, retailer inventory changes, and a delayed product launch are weighing on results in the near term.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 332.58M
- Float Shares
- 331.31M
of shares held by institutions
1,773 13F filers
Buy/sell ratio 2.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for KMB, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Aug 18, 26 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Oct 29, 24 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 30, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jun 2, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 1, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 13, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Nov 12, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 29, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 5, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jul 10, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jul 16, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 40.85M | ▲ 315.98K |
| Blackrock, Inc. | 32.32M | ▲ 2.12M |
| Vanguard Capital Management LLC | 21.66M | ▲ 116.11K |
| State Street Corp | 20.70M | ▼ 384.19K |
| Fmr LLC | 19.63M | ▲ 6.50M |
| Vanguard Portfolio Management LLC | 16.10M | ▼ 54.45K |
| Geode Capital Management, LLC | 11.44M | ▲ 238.03K |
| Charles Schwab Investment Management Inc | 10.81M | ▲ 1.15M |
| Sixth Street Partners Management Company, L.P. | 10.81M | ▲ 10.81M |
| Massachusetts Financial Services Co | 7.37M | ▼ 783.26K |
| Two Sigma Investments, LP | 7.05M | ▲ 1.88M |
| Bank Of America Corp | 6.88M | ▲ 219.74K |
Held by 2,163 ETFs
Biggest fund positions in KMB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | Wondrasch Michael | other | 0 |
| Nov 2, 26 | Wondrasch Michael | other | 0 |
| Nov 2, 26 | Wondrasch Michael | other | 0 |
| Nov 2, 26 | Halvorson Jonathan | other | 0 |
| Nov 2, 26 | Halvorson Jonathan | other | 0 |
| Nov 2, 26 | Dyer Russell | other | 0 |
| Nov 2, 26 | Dyer Russell | other | 0 |
| Nov 2, 26 | Dyer Russell | other | 0 |
| Nov 2, 26 | Dyer Russell | other | 0 |
| Nov 2, 26 | Dyer Russell | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KMB coverage
Recent articles, reports, and earnings notes.
Want a deeper read on KMB?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
